·AIM: To identify the pathogenic mutations in a Chinese pedigree affected with Usher syndrome type II(USH2).· METHODS: The ophthalmic examinations and audiometric tests were performed to ascertain the phenotype of the family. To detect the genetic defect,exons of 103 known RDs-associated genes including 12 Usher syndrome(USH) genes of the proband were captured and sequencing analysis was performed to exclude known genetic defects and find potential pathogenic mutations. Subsequently, candidate mutations were validated in his pedigree and 100 normal controls using polymerase chain reaction(PCR) and Sanger sequencing.·RESULTS: The patient in the family occurred hearing loss(HL) and retinitis pigmentosa(RP) without vestibular dysfunction, which were consistent with standards of classification for USH2. He carried the compound heterozygous mutations, c.721 C >T and c.1969 C >T, in the MYO7 A gene and the unaffected members carried only one of the two mutations. The mutations were not present in the 100 normal controls.· CONCLUSION: We suggested that the compound heterozygous mutations of the MYO7 A could lead to USH2, which had revealed distinguished clinical phenotypes associated with MYO7 A and expanded the spectrum of clinical phenotypes of the MYO7 A mutations. · AIM: To identify the pathogenic mutations in a Chinese pedigree affected with Usher syndrome type II (USH2). · METHODS: The ophthalmic examinations and audiometric tests were performed to ascertain the phenotype of the family. To detect the genetic defect, exons of 103 known RDs-associated genes including 12 Usher syndrome (USH) genes of the proband were captured and sequencing analysis was performed to exclude known genetic defects and find potential pathogenic mutations. RESULTS (PCR) and Sanger sequencing. RESULTS: The patient in the family occurred hearing loss (HL) and retinitis pigmentosa (RP) without vestibular dysfunction, which were consistent with standards of classification for USH2. He carried the compound heterozygous mutations, c .721 C> T and c.1969 C> T, in the MYO7 A gene and the unaffected members carried only one of the two mutations. The mutations were not pr esent in the 100 normal controls. · CONCLUSION: We suggested that the compound heterozygous mutations of the MYO7 A could lead to USH2, which had revealed prominence clinical phenotypes associated with MYO7 A and expanded the spectrum of clinical phenotypes of the MYO7 A mutations.